Cargando…

A new player in psoriatic arthritis: a JAK inhibitor

Detalles Bibliográficos
Autor principal:	Sakkas, Lazaros I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045999/ https://www.ncbi.nlm.nih.gov/pubmed/32185285 http://dx.doi.org/10.31138/mjr.28.4.210

Ejemplares similares

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
por: Sakkas, Lazaros I., et al.
Publicado: (2019)

The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis
por: Mavropoulos, Athanasios, et al.
Publicado: (2013)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Enterococcus gallinarum as a component of the Autoinfectome: the gut-liver-autoimmune rheumatic disease axis is alive and kicking
por: Bogdanos, Dimitrios P., et al.
Publicado: (2018)

JAK inhibition for treatment of psoriatic arthritis in Down syndrome
por: Pham, Andrew T., et al.
Publicado: (2021)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis
por: Sakkas, Lazaros I., et al.
Publicado: (2018)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
por: Sarabia, Samantha, et al.
Publicado: (2022)

Psoriatic arthritis synovial histopathology: commentary on the article by Kruithof and colleagues
por: FitzGerald, Oliver
Publicado: (2005)

Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype
por: Marchesoni, Antonio
Publicado: (2018)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

A Comment on JAK Inhibitors for Treatment of Alopecia Areata
por: Trüeb, Ralph Michel, et al.
Publicado: (2018)

JAK inhibitor, a new player for treatment-refractory microscopic colitis
por: Druez, Anne, et al.
Publicado: (2023)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis
por: Dorhoi, Anca
Publicado: (2015)

Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies
por: Lubrano, Ennio, et al.
Publicado: (2014)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Langley, Paul C
Publicado: (2020)

Psoriatic arthritis – new perspectives
por: Krakowski, Przemysław, et al.
Publicado: (2018)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

New Insights on Juvenile Psoriatic Arthritis
por: Brunello, Francesco, et al.
Publicado: (2022)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology
por: Jessica Chang, Ting Yi, et al.
Publicado: (2020)

The Infectious Basis of ACPA-Positive Rheumatoid Arthritis
por: Sakkas, Lazaros I., et al.
Publicado: (2017)

The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis
por: Kelepouri, Dimitra, et al.
Publicado: (2018)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

JAK inhibitors in systemic juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Circulating miRNAs as new activators of the JAK-STAT3 pathway
por: Lam, David, et al.
Publicado: (2013)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
por: Lubrano, Ennio, et al.
Publicado: (2022)

Syk: a new player in the field of breast cancer
por: Stewart, Zoe A, et al.
Publicado: (2001)

Commentary: ReadyPlayerOne: A new “reality?”
por: Krantz, Seth B.
Publicado: (2021)

Natriuretic Peptides: New Players in Energy Homeostasis
por: Moro, Cedric, et al.
Publicado: (2009)

Fabp4, a new player in the adipo-pancreatic axis
por: Ye, Risheng, et al.
Publicado: (2014)

Lymphangiogenesis: A new player in the heart's adaptive response to exercise
por: Dozic, Sanela, et al.
Publicado: (2022)

Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p74lb4u2pijd8c198hago8fl95